Mizuho Lowers Medtronic Price Target, Maintains Positive Outlook

Mizuho Securities analysts have lowered the price target for Medtronic (MDT) ahead of the company's upcoming first-quarter financial results. Despite the reduced target, the analysts stated they maintain their positive view on the medical device manufacturer. In their assessment, they highlighted some short-term factors and market conditions that led to the revision of the target price per share. They emphasized that the company's core business model and long-term growth potential remain solid. Mizuho's analyst team continues to view Medtronic's leading position in the sector and its innovation-focused strategy positively. The revision was said to be more related to external market dynamics and temporary operational factors rather than the company's overall performance. Investors are closely monitoring the first-quarter financial results, which the company is set to announce in the coming days, as well as management's forward guidance. These results are expected to be decisive for the stock's short-term performance. Analysts believe long-term demographic trends and technological advancements in the healthcare sector will continue to create opportunities for established players like Medtronic. Not investment advice.